SAN DIEGO, May 30, 2012 -- Genelux Corporation, a privately-held, clinical-stage biopharmaceutical company focused on development and commercialization of best–in-class, vaccinia-virus-based oncolytic viral therapies and companion diagnostics for cancer, today announced that data related to the company’s oncolytic virus therapy, GL-ONC1, will be covered by an abstract at the 2012 American Society of Clinical Oncology (ASCO) annual meeting from June 1st to June 5th in Chicago, IL. The data relate to the completed Phase 1 clinical trial of GL-ONC1 administered to patients with advanced solid tumors, which showed evidence of anti-tumor activity in 33% of patients (9 of 27).
"GL-ONC1, our leading product candidate, has been well-tolerated and shown encouraging results in early human trials against a number of solid tumor cancers. It is based on a novel product platform that delivers therapeutic and diagnostic constructs directly to tumors without harming healthy tissues or cells,” said Dr. Aladar A. Szalay, founder and CEO of Genelux Corporation.
Details of the poster session follow:
Abstract No. 2530: Phase I Clinical Trial of a Genetically Modified and Oncolytic Vaccinia Virus GL-ONC1 with Green Fluorescent Protein Imaging. Poster to be presented in S406 on June 2nd, 2012 from 8:00 a.m. to 12:00 p.m. and discussed in the Developmental Therapeutics – Clinical Pharmacology and Immunotherapy session immediately following from 12:00 pm to 1:00 pm in S406.
About Genelux Corporation
Headquartered in San Diego, California, Genelux Corporation is a privately held, clinical stage biopharmaceutical company dedicated to fundamentally changing the way in which cancer is diagnosed and treated. The company has developed a proprietary oncolytic virus-based technology platform featuring a companion optical imaging [luminescent/fluorescent] diagnostic capability on a therapeutic, replication-competent Lister strain vaccinia virus backbone. It is designed to selectively find and kill cancer cells without harming healthy tissues or cells. The platform can also be “customized” by inserting desired genes to effectively treat a variety of cancers and cancer-related conditions. The company is also incorporating advanced diagnostic deep-tissue imaging technologies into its viral platform to enable highly specific visualization of tumors and circulating cancer cells. GL-ONC1, the company’s lead oncology product candidate, is an attenuated (Lister strain) vaccinia virus currently under evaluation in human clinical trials in Europe and sponsored by Genelux GmbH, a wholly owned subsidiary of Genelux Corporation. Additional US- and European–based trials are set to begin imminently.
Genelux Forward Looking Statement
Statements made about Genelux Corporation, other than statements of historical fact, reflect Management’s current beliefs and assumptions founded on the data and information currently available to us. Statements of the company’s progress, results, timing of pre-clinical and clinical trials and projections for product pipelines are examples of forward-looking statements. By definition, such undertakings involve risks, uncertainties and assumptions, and are subject to a number of such factors that could cause actual results to differ substantially from statements made, including but not limited to: risks associated with the success of clinical trials, research and development programs, regulatory approval processes for clinical trials, competitive technologies and products, patents, inception and/or continuation of corporate and other strategic partnerships and the need for additional funding or financing.